Inclusion of pathogenic mechanisms in treatment design will allow ... and its more severe form NASH are common liver diseases in industrialized countries. Diabetes, obesity, the metabolic syndrome ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

No treatments currently exist for the fatty ... The condition represents a silent epidemic: a major cause of liver disease worldwide, NASH is now the number one cause of liver transplants for ...

Liver disease affects millions of adults in the United States, posing serious risks to health if left untreated. Among the ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a disease in which a buildup of fat causes inflammation and damage to the liver. It used to be called nonalcoholic steatohepatitis (NASH).

Cirrhosis is the severe scarring or fibrosis of the liver. It happens in the late stage of liver disease and other conditions that involve liver damage. The scarring that occurs with cirrhosis is ...

In the United States, 4.5 million adults live with diagnosed liver disease. For decades, Gilead Sciences has been a pioneer in the treatment of liver diseases, impacting patients worldwide ...

SAN MATEO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company ...

Biomarker staging of liver fibrosis in hepatitis C was cost effective, but so was initiating treatment without testing.

The Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH ... the treatment of patients with elevated LDL-C and non-alcoholic fatty liver disease ...